SARS treatment medications include salicylic acid, salicyclic acid, and phenoxyethanol, which are all used in treatment of SARS, and which are also used to treat certain types of allergies.
All of these drugs have been associated with a small number of deaths.
There are currently no treatments for SARS that are safe, effective, or well-tolerated in the United States.
SARS has been around for almost three decades, and the virus has spread around the world since 1976.
Sars is caused by the coronavirus, a virus that has caused around 1.4 million deaths and caused millions more to become sick.
The U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) classify SARS as a pandemic, meaning it is becoming more severe and more severe diseases are emerging in the Western world.
The new study, published in the journal JAMA Internal Medicine, looked at deaths due to SARS in the U.K. and Canada.
The authors say that deaths are likely to rise in coming years due to the virus’ spreading and that treatment is essential.
The researchers also report that people may become resistant to these drugs, and therefore may die earlier.
Here are some of the other new findings from the study: SARS mortality rates are higher in countries that have more treatment options.
In a study published in December, researchers from Harvard University and the University of Toronto found that mortality rates were higher in the countries with fewer treatments.
That means that in many cases, people may be treated sooner in the developed world and later in the developing world.
They also found that people who died from SARS tended to have higher baseline rates of other chronic diseases, which could be why the mortality rates increased in countries with less treatment options and lower levels of treatment.
The study authors suggest that the more advanced countries might be able to treat people earlier.
The US has been the epicenter of the pandemic.
As of February 28, more than 11.6 million people were infected with the virus.
The United States is home to more than half of the world’s total cases, with 1.3 million deaths.
The country is also home to the most SARS deaths, with 2.7 million.
Many of the infections have been concentrated in the cities and rural areas of the United State, with a high rate of hospitalizations and deaths.
“In the U: The US and the Global Outbreak of Sars, we document the geographic and temporal clustering of SAR cases and fatalities in developed countries, particularly in the US and Canada,” said lead author Dr. J. Ryan Bailey, a research fellow at Harvard’s Chan School of Public Health and the co-director of the SARS Epidemiology and Control Center at the University at Buffalo.
“We find that SARS patients in developed, industrialized countries in particular are at higher risk for mortality, and that this is especially true in the western U. S. and western Canada, where treatment options have improved and more advanced treatments are available.”
He added that the study also looked at mortality rates from all the drugs that were tested in the study.
“There are a number of medications that are commonly used to manage SARS and are associated with lower mortality and morbidity.
In fact, some of these medications may have the potential to slow the progression of the virus,” said Bailey.
“Some of the medications may not have been available in the pre-clinical stage before SARS.”
For example, there is currently no treatment for salicyric acid, which is often used to reduce swelling in people with allergies.
Bailey said that salicylimic acid is a class of antibiotics known as cephalosporins that have been used in the treatment of allergies since the 1970s.
It is also a class that has a limited ability to kill the virus because it is not active against all the viruses that are in circulation.
“It may be that salicylates might be less effective against SARS than other drugs and therefore would have a lower effect against Sars,” Bailey said.
Bailey and his colleagues say that it is unlikely that these drugs will be effective in the future.
“Given the increasing prevalence of SRS, we are concerned that these medications will not be able or will not have the ability to reduce the incidence of SIRV in the long-term,” they write.
“These data also suggest that we need to explore other possible treatment options to better manage the SIRS pandemic.”
Other research also suggests that the new findings will have an impact on the way patients and doctors respond to SIRVs, as they can be very difficult to predict.
Dr. Andrew Schaller, director of the Center for Healthcare and Society at the Harvard School of Engineering and Applied Sciences (SEAS), says that there are a lot of things that we still don